Garuda Therapeutics
11:30 AM - 11:45 AM (EDT), Tuesday, June 6, 2023 ・ Session Room 103
Garuda is developing the world’s first, off-the-shelf hematopoietic stem cell platform that will eliminate dependency on donor or patient cells.
Currently, patients seeking a blood stem cell transplant must find a suitable human donor as a source of blood stem cells. Unfortunately, racial minorities face greater barriers than white patients in finding suitable blood stem cell matches. Garuda’s platform for generating self-renewing blood stem cells is designed to provide patients with rapid and broad access to consistent, durable, HLA-matched transgene-free blood stem cell therapies.
Like bone marrow transplants, Garuda’s technology has the potential to address, and possibly cure, more than 120 diseases including hematologic malignancies, sickle cell disease, β-thalassemia and bone marrow failure diseases. It also overcomes many limitations of current practices and could potentially offer treatment options to patients irrespective of their racial background.
Currently, patients seeking a blood stem cell transplant must find a suitable human donor as a source of blood stem cells. Unfortunately, racial minorities face greater barriers than white patients in finding suitable blood stem cell matches. Garuda’s platform for generating self-renewing blood stem cells is designed to provide patients with rapid and broad access to consistent, durable, HLA-matched transgene-free blood stem cell therapies.
Like bone marrow transplants, Garuda’s technology has the potential to address, and possibly cure, more than 120 diseases including hematologic malignancies, sickle cell disease, β-thalassemia and bone marrow failure diseases. It also overcomes many limitations of current practices and could potentially offer treatment options to patients irrespective of their racial background.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2021
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
Off-the-shelf hematopoietic stem cells
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4+ assets
Speaker
